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Calcification is linked to a high prevalence of cardiovascular events and mortality due to
arterial stiffness. Stiffening of the arteries in the case of medial calcification is due to
hydroxyapatite mineral deposited in the artery thus leading to the loss of elastin. A possibility of
removing this rogue mineral along the vessel walls could be the use of osteoclasts. Osteoclasts, a
type of osteocyte, have the unique ability to absorb bone in the bone turnover process. It is
proposed that in the future, osteoclasts be delivered to the site of mineralization through oxidized
alginate-fibrin microbeads. Alginate hydrogels have proven great in drug delivery and could be a
revolutionary cell delivery device to provide care for multitudes of people suffering from
adjacent cardiovascular health problems such as arterial stiffness.
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CHAPTER I
INTRODUCTION

Cardiovascular disease prevalence
Cardiovascular disease is the leading cause of death in the United States and is one of the
top causes of death worldwide [1]. Not only are cardiovascular diseases deadly, but they are also
costly. It was estimated from 2014 to 2015 the United States alone spent 219 billion dollars on
heart disease or issues related to heart disease, including loss of labor due to deaths [2].
Cardiovascular disease has become a profoundly severe problem that many are trying find a
solution. One solution for decreasing mortality from cardiovascular disease could lie in
attempting to correct cardiovascular calcification. Vascular calcification in arteries is linked to a
high prevalence of cardiovascular events and mortality due to arterial stiffness. Stiffening of the
arteries, in the case of medial calcification, is due to hydroxyapatite mineral being deposited in
the media tunica artery and the loss of elastin [3]. Currently the most effective treatment for this
disease is balloon angioplasty. A high-pressure balloon angioplasty involves placing stent in the
artery where calcification is present [4]. This however is a temporary fix as the calcification
would eventually grow around and attempt to close the artery. This treatment is also risk free for
the patient as they could experience swelling, pain, and infection at the catheter site. A
possibility of removing this rogue mineral in the vessel walls could be the use of alginate.
Alginate is commonly used as a drug delivery vehicle due to its ability to easily become a
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hydrogel, biocompatibility, and controllable degradation rate. This polymer would aid in the
transport of osteoclasts to the area of calcification in the artery. Osteoclasts, derived from the
monocyte lineage, are the only cell type known to have to ability to resorb bone [5]. Thus,
osteoclasts could be incredibly useful in a cell therapy to treat vascular calcification and people
suffering from adjacent cardiovascular health problems such as arterial stiffness.
Vascular Calcification Overview
Vascular calcification or better known simply as VC, serves as an indicator for
cardiovascular disease. If VC could be resolved, cardiovascular diseases could be lessened in
frequency. The calcification process is an active cell process in which vascular smooth muscle
cells (VSMCs) found in the vessel wall differentiate into osteoblast-like cells. In the normal bone
turnover process, either mesenchymal cells will differentiate into osteoblasts to form bone, or
cartilage is first laid down then osteoblasts take over [6]. It is theorized that medial VC follows
the first process as VSMCs and osteoblasts both originate from mesenchymal stem cells [7]. In
medial calcification, these osteoblast-like cells spread all throughout the vessel and begin
depositing hydroxyapatite mineral in the tunica media of the artery. By contrast, intimal
calcification is recognized as plaque deposits in the vessel which results in inflammation and
thus is commonly associated with atherosclerosis [8]. These two processes of calcification can be
seen in Figure 1 where intimal calcification is seen as a localized plaque buildup while media
calcification is a more generalized calcification process as the VSMCs are undergoing this
change into osteoblast-like cells. In comparison to intimal calcification, medial calcification has
more of an effect on the elastic properties of the artery while intimal calcification results in
arterial lesions and atherosclerosis due to plaque buildup. This is due to calcium mineral being
primarily being deposited in areas of the ECM where elastin is present.
2

While both forms of calcification are damaging and lead to coronary complications and
risk, they have different processes. In this study medial calcification will be the focus as the
process involves the differentiation of vascular smooth muscle cells [6].

Figure 1

Classifying Intimal and Medial calcification

Chart highlighting the differences between the two types of calcification in the arteries [6]
Medial Calcification
Medial calcification is most typically associated with end stage renal disease, diabetes
mellitus, Monckeberg’s sclerosis, hypertension and osteoporosis [6], [9]. The key features found
in medial calcification are that this type of calcification highly resembles formation of the skull
and teeth, Msx2 (muscle segment homeobox 2) regulates medial VC, and medial calcification
starts with vesicles in association with fibrillar collagen extracellular matrix (ECM)[10], [11]. In
the first key feature of medial VC, resembling bone and teeth formation, explains how the
calcium mineral is deposited in the artery. The bone mineralization of the skull is done by
intramembranous ossification which simply means that thin layers of bone are directly deposited
on connective tissue [12]. In medial calcification, these osteoblast-like cells deposit mineral,
3

carbonated hydroxyapatite (CHA), into the medial tunica mainly on or along the elastin rich
elastic laminae through the aid of extracellular vesicles[13], [14]. This calcium deposition is
different than what is normally seen in the bone turnover process from osteoblast cells. A study
showed the mineral deposition in medial calcification goes through the steps of: adsorption of Ca
ions, formation of amorphous calcium phosphate (ACP) and octacalcium phosphate (OCP),
transformation to HA then finally CHA [14]. This CHA deposit is especially dangerous as this
calcification leads to intensifying of current diseases like chronic kidney disease or onset of heart
disease due to arterial stiffening. The deposition and generation of CHA is due in part to the
osteogenic expression taken on by VSMCs but could also be due to genetic predisposition, toxins
in the body or decreased levels of calcification inhibitors [7].
Inducers of Vascular Calcification
The differentiation of VSMCs into osteoblast-like cells can be caused by a multitude of
factors such as outside stress on the body causing altered levels of proteins or compounds. Other
causes are loss of calcification inhibitors, apoptosis of VSMCs, aging, DNA damage response
signaling and disorders that disrupt the calcium-phosphate homeostasis in the body [15].
Age related inducers
Age-related calcification becomes more likely due to senescence of VSMCs. Senescent
increases with age and senescent VSMCs have been analyzed and have been found to show a
osteoblastic markers in addition to a pro-inflammatory phenotype [6], [16]. Age affects VSMCs
just as it does the composition of the ECM. The vascular ECM sees an increase in fat and
calcium crystals with age which could explain the increased calcium levels seen VC patients
[17].
4

Calcium and phosphate levels
Some of the most known well-known causes for VC are heightened levels of both
calcium and phosphate. An experiment was done in which human aortic smooth muscle cells
were used see if these cells underwent differentiation when exposed to increased phosphate
levels. Cbfa-1 and osteocalcin, both osteoblastic differentiation markers, were expressed under
these conditions. Pit-1 was also identified as part of the study as sodium-dependent phosphate
cotransporter aided in transporting excess phosphate into the cell which promotes osteoblastic
expression [18]. This osteoblastic expression causes smooth muscle gene expression to decrease
due to the rising expression of osteoblastic genes such as Cbfa-1 (also known as Runx2),
osteocalcin and osteopontin [19], [20]. This process is pictured in Figure 2 where sodium
phosphate is introduced to a VSMC in excess through Pit-1 and the rise of phosphate causes the
rise of the expression of Cbfa-1 and decrease in expression of VSMC genes. The enzyme
complex, nicotinamide adenine dinucleotide phosphate oxidase and increase of hydrogen
peroxide results in increased causes Cbfa-1 expression which then stimulates VSMCs to
differentiate into osteoblast-like cells [16].
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Figure 2

Hyperphosphatemia in VSMCs

Process of VSMCs undergoing osteoblastic differentiation due to upregulation of phosphate [11]
In conjunction with this, an increase in calcium, phosphate, BMP-2 or mechanical
stimulation can cause a phenotype switch in VSMCs to osteoblast-like cells which lead to
deposition of CHA [6]. Calcium was also seen to upregulate Pit-1 expression which allows
inorganic phosphate to be transported more readily into the cell [11], [19]. In the case of chronic
kidney disease, patients often experience hyperphosphatemia which is known to induce vascular
calcification in individuals. High phosphate causes an upregulation of Cbfa-1 which then induces
the VSMCs to differentiate into the osteoblast-like cells. The high phosphate levels in the body
also contribute to the CHA deposition as the mineral is made of calcium and phosphate. These
high levels of phosphate also cause a decrease in the production of calcification inhibitors which
enable an increase in unregulated calcium in the blood [3].
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BMP-2 and Msx2
Altered levels of the bone morphogenic protein BMP-2 and Msx2 (developmental
homeobox-related transcription factors) have also been seen to affect VC in medial tunica. BMP2 is a critical bone forming signaling molecule that along with calcium as mentioned previously,
has been seen to upregulate Pit-1 [11]. Upregulation of Pit-1 results in an enhanced calcification
in the artery due to increased uptake of inorganic phosphate. BMP-2 has a direct relationship
with Msx2 as it upregulates Msx2, an osteogenic transcription factor [21]. When an elevated
level of Msx2 is expressed it causes the increased expression of Cfba-1 [16]. In conjunction with
this, an increase in calcium, phosphate, BMP-2 or mechanical stimulation can cause a phenotype
switch in VSMCs to osteoblast-like cells which lead to deposition of CHA [6].
The ECM and top two proteins
The ECM is an incredibly diverse structure made up cells, proteins, and macromolecules.
This structure is involved in maintaining cell: homeostasis, processes, migration and survival
among other things [22]. Specifically, the vascular ECM is responsible for mechanical support,
elasticity of the artery and impact cell physiology among many other things [23]. The top two
most prominent proteins in the vascular ECM are collagen and elastin. Elastin is vital to the
artery as it provides elasticity and mature elastic fibers typically last for a person’s lifetime so if
damaged cannot be repaired [24]. Collagen provides mechanical strength and structure to the
vessel wall. These proteins can regulate this process and initiate the coagulation pathway.
Collagen types I, III and VI make up most of medial layer of the artery with collagen type I
making up 60% of all vascular collagen [25]. These three types of collagen constitute what is
known as the interstitial membrane. This part of the ECM is a hydrated gel that fills the space
between cells and is in both the medial and intimal section of the artery (Figure 3). The
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interstitial membrane also acts a compressive buffer as it contains collagen as well as salts,
fluids, and polysaccharides. Interestingly, the collagen types I and III contain VWF-C (von
Willebrand factor type C) domains which have been seen to play a role in regulating BMP [25].

Figure 3

Layers of the artery

Layers of an artery highlighting types of collagen found in each membrane and layer [25]
Arterial Stiffness
As a person ages, regardless of cardiovascular disease, the composition of the ECM will
alter. The amount of collagen in the body increases thus causing the amount of elastin to
decrease leading to stiffening of the arteries [24]. The mechanical load is then placed on collagen
rather than elastin, with collagen being much stiffer than elastin. This stiffness is critical as it can
lead to cardiovascular events in the future due to the arteries not having their previous elasticity.
The elastic lamellae also see a change as they appear ruptured and fragmented due to repeated
8

use and the remaining elastin becomes calcified. The calcification is due to CHA being deposited
at lipid vesicles that are along and between elastic laminae in the process of medial calcification
[26]. Other stressors besides age cause changes to the ECM composition.
Phenotypic Switch and MMPs
Normally in the artery a contractile phenotype of VSMC is seen but cases of injury or
stress, VSMCs undergo a change in phenotype to that of synthetic. These synthetic VSMCs
release matrix-metalloproteinases (MMPs) to aid in vascular repair [17]. This phenotypic switch
from contractile VSMC to synthetic is seen in Figure 4.

Figure 4

Diagram of phenotypes of VSMCs

Describing contractile VSMCs become synthetic VSMCs, thus releasing MMPs for vascular
repair. Or how contractile VSMCs become osteogenic VSMCs releasing MMPs that lead to
vascular calcification. [17]
9

The release of MMPs from synthetic VSMC is meant to aid the artery wall in times of
stress but can cause arterial stiffness as these synthetic VSMCs are regulating the remodeling of
the ECM. This increase in MMP, specifically 2,7,9,14 have been seen to be important to the
arterial ECM remodeling [24]. In addition to injury or stress, as a person ages or has had chronic
high blood pressure, MMPs react by initiating the breakdown of elastin in the ECM due to
increased synthetic VSMCs reacting to mechanical stress. To make up for the loss of elastin, the
synthetic VSMCs produce collagen in an attempt to stabilize the ECM environment[17]. This
loss of elastin with the addition of collagen and deposited CHA by osteogenic VSMCs leads to
arterial stiffness in VC.
Hypertension related to arterial stiffness
Arterial stiffness is measured by pulse wave velocity which if results in a higher-thannormal velocity, is an indicator of hypertension. Hypertension is known to be a calcification
inducing stressor and is due to loss of normal elastin which most commonly occurs with age or
other stressors as explained above. [27]. Hypertension also aids in VC by promoting arterial
stiffness through alteration of the ECM [28]. This alteration to the ECM causes an abnormal
elastin to take over the ECM which causes the arteries to lose their elasticity and harden.
Hypertension in correlation with medial calcification is a feedback loop in that both diseases feed
into each other. Medial calcification can worsen hypertension by decreasing elastin in the vessel
and hypertension is a VC stressor. Hypertension causes an increase of pulse wave velocity and
pulse pressure which causes an mechanical stress on the artery [27]. Overall, through age, cell
death, disease, or other cause an abnormal ECM environment causes VSMCs to differentiate
thus progressing the cycle of vascular calcification.
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Calcification Paradox
Deposition of mineral from the osteoblast-like cells is correlated with a decreased bone
density. This phenomenon is known as the calcification paradox. It has been observed in chronic
kidney disease and osteoporosis patients [6]. In addition, this paper by Persy and D’Haese
highlights the potential success with use of osteoclasts to absorb the hydroxyapatite mineral as
these cells can do so without harming the ECM [6].
Osteoblasts
The counterpart to osteoclasts and the cell that has been discussed most through this
paper are osteoblasts. Osteoblasts are known for their ability to build bone through their unique
structure. This structure encompasses an increased amount of rough endoplasmic reticulum
necessary to produce collagen rich bone [29]. Interestingly it was discovered that when
compared to osteoblasts that originated directly from mesenchymal stem cells and those that
transdifferentiated from VSMCs, those from VSMCs had a lower amount of mRNA gene
expression levels of osteoblastic markers such as Runx2, Sp7, Alpl, Bglap2 and Spp1 present
[30]. This concludes that these osteoblast cells derived from VSMCs are not mature osteoblasts
as one would expect to see in the body but are rather in the early stages of differentiation [31].
There was a finding that concluding that the osteoblast-cells deriving from VSMCs behaved
differently than regular osteoblast cells. In a natural process, osteoblast cells usually start the
bone turnover process which involves osteoclasts while the osteoblast-like cells inhibit any
osteoclast activity pertaining to the deposited mineral [6].
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Osteoclasts
Osteoclasts like osteoblasts are unique and important in combating VC. As previously
mentioned, osteoclasts and osteoblasts typically have a balanced relationship in the bone
turnover process. Just as osteoblast cells create the bone matrix, osteoclast cells are responsible
for bone resorption. Once attached to a bone surface osteoclast cells will acidify the mineral part
of the bone and secrete enzymes to degrade the rest of the bone matrix [29]. There are several
steps that must happen before osteoclasts are able to resorb bone. The steps are as follows: the
proliferation of osteoclast progenitors, differentiation of those progenitors into mononuclear
prefusion osteoclasts (pOCs), fusion of pOCs into multinucleated osteoclasts, then migration of
osteoclasts to the resorption site. Osteoclasts are guided to sites of resorption by receptors like
those found in the protein osteopontin that will be mentioned later in the text. Once at the site,
the osteoclasts create a seal zone which allows for the polarization of osteoclasts and promotes
the directional secretion of acid and enzymes for dissolving bone mineral [32]. A promising
experiment showed that osteoclasts could absorb hydroxyapatite, which is the mineral deposited
by osteoblast-like cells in VC [33]. Osteoclasts are a critical part of the proposed cell therapy as
they will resorb the harmful CHA mineral from the vascular walls.
Targeting Calcification
In terms of a targeting mechanisms for the osteoclasts to bind to CHA produced by VSMCs, the
injection method as mentioned previously is helpful in specifying the delivery site, but targeting
would enhance the therapy’s potential. One option is using human vitronectin (Vn) to target the
CHA in the arteries. Recently there has been research discovering that Vn has high affinity to
bind to solid HA[48]. Coating the beads with a layer of Vn will allow the beads to be led to CHA
with more specificity. In addition to the use of Vn, a layer of silk fibroin will also be added, not
12

to target but to offer more stability to the microbead. Silk fibroin has been previously used
successfully with alginate microbeads and has shown that it slowed the beads degradation while
also providing mechanical strength[49]. If this were to work this would be highly beneficial in
this cell therapy in the microbeads being able to specifically target areas of calcification.
Successful and Early-Stage Cell Therapies
Cell therapies have been quite successful, bone marrow transplant has been repeatedly
used and around for over 40 years [34]. Bone marrow transplants involve the use of transferring
adult stem cells from one person to another in hopes of treating a multitude of diseases such as
leukemia and POEMS syndrome [35]. Another cell therapy has shown to reduce the chance of
relapse in cancer patients by 80% using chimeric antigen receptor (CAR) T cells. These CAR T
cells are taken from the patients’ blood and engineered to express receptors that target a specific
tumor antigen [36]. Both therapies use allograft or autograft stem cells and are both successful in
treating the disease.
Some cell therapies in preliminary stages of clinical trials are treatments for Parkinson’s
Disease and burns to name a few. In relation to Parkinson’s Disease, two clinical trials with the
use of fetal nigral cells showed an increase dopamine uptake in patients [37]. These trials were
done in 1988, and when the trials were conducted again it was found that the recovery of older
patients was not as significant as younger. This has led to a revamped look at this cell therapy
using stem cells. These trials are still underway and researchers are hopeful with insurgence of
technology around induced pluripotent stem cells [37]. In treatment of burns, stem cells have
been used and have shown to increased healing rate, expression of vascular endothelial growth
factor and decreased inflammation as seen by lower levels of Interleuikin-1 when compared to
the control group. This study was only done in animals but shows promise in treatment of severe
13

burns which are very painful, have a long healing time and according to the World Health
Organization burns account for about 300,000 deaths each year [38].
While all these cell therapies utilize cells, an additional obstacle to overcome with the
proposed cell therapy is that the osteoclasts encapsulated in the microbead must have a targeting
mechanism to it. This target will aid in allowing the cells to go directly to the area of
calcification.
Oxidized Alginate Microbead Cell Therapy
The cell therapy proposed to combat VC would eventually involve the use of osteoclasts.
These osteoclasts would be delivered via intramuscular injection to the area of calcification via
alginate microbeads and will break down the bone-like mineral that is deposited by the
osteoblast-like cells. This injection of osteoclasts will reduce calcification and thus reduce side
effects produced from VC. Reduction of mineral in vessels may also reduce arterial stiffness and
return bone turnover homeostasis. The proposed cell therapy will not completely heal the patient
if they are suffering from an additional cardiovascular disease such as hypertension and other
factors must be taken into effect such as medical management and lifestyle changes.
Components of delivery method
This proposed delivery method is primarily abstracted from a paper by Zhou and Xu in
which they used all same components except instead of osteoclasts, osteoblasts were used. There
are several components involved in the creation of these microbeads. The main component of the
microbead is alginate which was oxidized using sodium periodate then created into a hydrogel by
means of dripping the alginate solution into calcium chloride to crosslink. Alginate is oxidized so
its degradation can be more easily controlled by means of having a designated amount of sodium
14

periodate associated with degradation rate. This natural polymer derived from seaweed, is
biocompatible and has frequently been used in many drug delivery applications due to its
previously mentioned ability to become a hydrogel [39]. Fibrin is another component of the
proposed delivery method. It is a natural fibrous protein that is also biocompatible and
biodegradable. The fibrin would function as a scaffold for the osteoclast cells to attach to. As
mentioned previously osteoclasts are essential as they would be providing the needed therapy for
the patient in removing the CHA from the artery.
Results from article by Zhou and Xu
In Zhou and Xu, all main components: fibrin and oxidized alginate were combined in
subsequent steps to create microbeads that within them held stem cells. This paper then
expanded to assess the microbeads’ viability, toxicity, degradation rate and osteogenic gene
expression. In assessing the microbeads’ degradation rate a 21 day was conducted as seen in
Figure 5. At day 4 the beads began to degrade as the red arrows indicate the breakdown of the
alginate membrane[40]. By day 14 the cells incapsulated in the beads were released as the beads
had completed degraded. The successful release of the cells is further exemplified by Figure 6. In
this, cells can be seen beginning at day 4 when the microbead begins to degrade and only
increase as the days go on. Again, by day 14 the cells are very confluent covering the surface and
spreading out. This research gives promise for the proposed delivery method to be successful.
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Figure 5

Degradation of Oxidized Alginate Fibrin Microbeads

Degradation of beads at days 1-21, red arrows indicating areas of degradation [40]
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Figure 6

Live/Dead Assay of Oxidized Alginate Fibrin Microbeads

Assay showing viability of stem cells starting at day 1 ending at day 21. The green indicates live
cells while red is indicative of dead cells. After 21 days, in image F, there are overwhelming
more live cells than dead that were released from the microbeads. [40]
Components of Proposed Delivery Method
As mentioned before the main component of the cell therapy would involve turning
alginate into a hydrogel. A hydrogel is a common drug or cell delivery device as it can be easily
delivered, fill abstract spaces, and can mimic the ECM [41]. Divalent cations like Ca2+ bind to
17

the G blocks of alginate which allow alginate to form gels. G block residues form cavities that
attract ions such as Ca2+. In terms of flexibility of blocks MG, MM then GG being the most
inflexible [42]. In this way the Ca2+ ions bind to -COO- group on the polymannurate section of
calcium alginate. Once bonded through chelation, an “egg-box” structure is formed which allows
the alginate to form beads[43]. Alginate as mentioned previously was used in the experiment and
created into microbeads but alginate gel itself is very unpredictable in its degradation rate.
Sodium periodate has been used in several experiments and has been proven to control the
degradation rate of alginate hydrogels by means of oxidation. When the carbon-carbon bond of
the cis-diol group in uronate residue of alginate is cleaved by sodium periodate and altered, the
chair conformation is changed to an open chain adduct allowing a more controllable degradation
as seen in Figure 7 [44]. It has been shown through experimentation that alginate microbeads
degrade through an increase of swelling until bursting. This is done through a molecular
exchange in the “egg-box” for Na+ for Ca2+ ions. After this exchange more water is taken into
the bead leading to eventually degradation [43].

Figure 7

Alginate Chair Conformation

Alginate undergoing oxidation via sodium periodate through a chair conformation [41]
Alginate itself without being oxidized is biocompatible so a study was done to test
whether oxidized alginate maintained this desirable quality. The experiment proved that no
changes of biocompatibility could be seen and still could promote cell interaction just the same
18

as non-oxidized alginate [41]. In terms of what percent of oxidation 1-8% has been used with
varying success so this must be tested.
Injection method
Intramuscular injection of this cell therapy has many advantages as well as some
disadvantages. This form of delivery is minimally invasive and as such would produce little pain
from the patient and thus faster recovery time. Also, with injection the site of delivery can be
specified. There are some things when dealing with injection techniques that must be considered
especially when dealing with cells. One major factor is shear forces in the syringe. In response to
forces that the microbeads will encounter when being delivered the mechanical properties of
alginate can be altered as it can be prepared in a variety of molecular weights [45]. It was shown
in a study that alginate hydrogel with a lower molecular weight, 75kDa, was able to protect cells
when passed through a needle and thus lead to a greater cell viability [46].
Microbead Creation
The microbeads would be created by cross-linking oxidized alginate with a soluble salt of
divalent, calcium chloride (CaCl2). Before being formed, oxidized alginate would be combined
with fibrin to encourage cell-matrix interaction as on its own alginate is bioinert. Fibrin is
polymerized from both fibrinogen and thrombin and is biodegradable and biocompatible. It has
been shown that within the fibrin matrix promotes cell proliferation and differentiation [40],
[47]. The beads would be formed by dripping the prepared alginate solution into aqueous CaCl2
with the size of the beads depending on the size of the needle they are dropped from and stir rate
[45].
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Conclusion
In conclusion, the cell therapy involving oxidized alginate-fibrin microbeads
encapsulated with osteoclasts shows promise to remove deposited mineral by VSMCs that have
undergone a phenotypic switch either due to pathologic or stress induced means. If successful,
this therapy could reduce the risk of death from cardiovascular disease or cardiovascular related
diseases as vascular calcification is a precursor or adjacent factor to other heart ailments. This
would be the first successful treatment of cardiovascular calcification via cell therapy rather than
by the more intrusive surgical means and a treatment that would remove the problem rather than
just give the patient a quick fix as a stent would. As mentioned previously, there have been other
studies working with oxidized alginate microbeads, but no further in-vivo studies have yet to be
published. These studies focused on restoring lost bone due to osteoporosis or other diseases
with the use of osteoblasts. In our study our goal is to create oxidized alginate fibrin microbeads,
determine the oxidation percentage of alginate solutions, determine degradation rates and cell
encapsulation efficiency of the proposed microbeads. We plan to address the research question of
whether oxidized alginate microbeads can be used as cell delivery device to cells for our
proposed cell therapy.
Specific Aim 1: Create and characterize the morphology of oxidized alginate fibrin microbeads.
Oxidation measurement of beads
Creation of beads
SEM imaging of beads
Specific Aim 2: Examine degradation of alginate beads and efficiency of cell encapsulation
Degradation study of differing percentages of oxidation
Degradation study of beads with cells
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Live/Dead assay during degradation study
It is hypothesized from published literature that oxidized alginate microbeads
would be an excellent candidate for a cell delivery device due to its biocompatibility and
controllable degradation. Based on literature review oxidized alginate fibrin microbeads can be
created and encapsulate cells at various oxidation percentages.
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CHAPTER II
AIM I: CREATE AND CHARACTERIZE THE MORPHOLOGY THE OF OXIDIZED
ALGINATE MICROBEADS
Introduction
Alginate hydrogels have been used before due to the polymer’s desirable qualities, but
oxidized fibrin microbeads are still a new product. Oxidation of alginate has been largely known
to cause controllable degradation of alginate since the 2000’s and even theorized in the
1970’s[50], [51]. Fibrin while not widely used in conjunction with oxidized alginate has been
used successfully in the experiment conducted by Zhou and Xu. Thus, our lab has followed the
latter’s procedure for making the oxidized alginate fibrin microbeads and has shown that the
beads can be made. Due to the studies done by the lab being done a few years ago it was
necessary to reaffirm the study to ensure that the method was viable. Through trial and error,
some changes were made in which an edited method was created in which beads could be
created in a more effective manner.
As previously mentioned, the oxidation of alginate has benefits in that it alters the
molecular composition of alginate making it more susceptible to hydrolysis. If the alginate
hydrogel were not to be oxidized its degradation would be extremely slow over time. With
oxidation the rate of degradation can be controlled by means of the amount of sodium periodate
used. The amount of sodium periodate used corresponds to the oxidation percentage, or the
amount of sodium periodate consumed in the 24-hour reaction period. This value needed to be
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calculated to discover the oxidation percentage that coincides with mass of sodium periodate
used. It has previously been reported in literature that certain percentages of sodium periodate,
such as 5%-7.5% provide the best working alginate microbeads in terms of degradation and
mechanical strength[40], [44], [52]. Along with the changing the chair conformation of alginate,
the surface morphology of the alginate bead must be investigated to understand how the varying
oxidation percentages of affect the bead. A range of varying masses of sodium periodate were
added to solutions of sodium alginate to test the products ability to firstly create a viable bead
then to determine its degradation potential corresponding with the oxidation percentage.
Aim I Specific Objectives
The objectives of these studies are to firstly create alginate microbeads through a method
that can be repeated. Once created, the surface morphology of the standard alginate bead without
oxidation versus a bead that had undergone oxidation via SEM must be examined to determine
differences between the control and other oxidized beads. To proceed with the degradation of the
beads, their oxidation percentage first had to be determined through absorbance measurements
and a standard curve equation.
Experimental Section
Materials/Methods
Creation of alginate microbeads
Sodium alginate (1g) was slowly added to 100mL of distilled water (DI) in a 250mL
beaker. Depending on the desired oxidation, sodium periodate was first dissolved in 1.51mL of
DI water before being added to the sodium alginate solution. This solution was covered and left
to stir for 24 hours at room temperature before oxidation was stopped. 1g of ethylene glycol then
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2.5g of NaCl were used to stop oxidation. Once oxidation was stopped the solution was added to
centrifuge tubes (50mL) to be transported to Hand Lab. 15mL of oxidized sodium alginate
mixture were added to polycarbonate 50mL centrifuge tubes. In each centrifuge tube 35mL of
ethanol was added to precipitate the alginate product before centrifugation. Centrifuge tubes
were weighed in pairs to ensure a difference of 0.2g between the two. Centrifugation was done at
6000rpm for 10 minutes at 20 degrees Celsius. After centrifugation, the excess ethanol was
dumped off and the product was washed with 100mL of DI water. The precipitate was then
secondly precipitated with 100mL of ethanol. This product was collected either through spatula
or strainer depending on the size. Once collected the precipitate was washed with 30mL of DI
water and stored at -80-degree Celsius freezer for 24 hours. After the 24 hours in the freezer the
oxidized sodium alginate product was freeze dried overnight or at least for 12 hours. The freezedried product should be porous and white, cracking easily. A saline mixture 155mmol/L of NaCl
was created then 1.2% of alginate product by mass was added. At 0.1% by mass fibrinogen was
added to the solution. This solution was then covered and incubated at 37 degrees Celsius and
stirring at 100rpm for 2 hours. After the 2 hours, the solution was brought out of the incubator
and the crosslinking solution containing 125mL of DI water, 100mmol/L CaCl2 and 125 NIH
units of thrombin was created. The mass of thrombin varied depending on the NIH units of
protein on the sample. The crosslinking solution was stirred until it was clear, then the dropping
apparatus was set up. This consisted of single syringe pump, a 10mL soft-ject syringe,18-gauge
needle, and Fisher Scientific Syringe Pump for controlled release of the alginate solution. The
apparatus was set up to 180mL/hr. Once the oxidized alginate-fibrinogen solution fell into the
crosslinking solution beads were formed while also creating fibrin with the combination of
fibrinogen and thrombin.
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Determining of Oxidation Percentage
Before stopping oxidation with the aid of ethylene glycol and sodium chloride, 5mL of
sodium alginate solution were set aside for oxidation percentage. A 20mL of DI water was mixed
with 1.42 g of sodium phosphate at low temperature. On average 16-20 drops of 0.6M of HCl
were added to adjust the pH of the solution to 7. The created buffer was equally divided and 2g
of potassium iodide and 1g of thyodene were added to their respective buffer solutions. All steps
involving potassium iodide and thyodene were done in a dark room. A serial dilution of 1M of
sodium periodate was created to establish a standard curve for calculation of the oxidation
percentage. In a 96 well plate 100µL of sodium alginate sample with repeats of four for accuracy
and 100µL for each serial dilution were placed in wells. The two 10mL solutions of potassium
iodide and thyodene were combined and used in 100µL in each well that was being tested for
absorbance. The plate was then read spectrophotometrically at 486nm from Bio-Tek µQuant
Microplate Spectrophotometer. These values from the read absorbance and the equation gained
from the standard curve were used to calculate oxidation percentage.
Calculation Degree of Oxidation
From the absorbance values obtained from the serial dilution of 1M of sodium periodate,
a standard curve was created. An equation was obtained which is written out below where x is
molarity and y symbolized absorbance.
𝑦 = 10222𝑥 + 0.0654

(1)

The calculation to determine the oxidation percentage was done by first determining the
concentration from the absorbance. This concentration was labeled M1 and was the
concentration of the amount of sodium periodate that was consumed during the twenty-four-hour
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period reaction. Then M1 was subtracted from M, which symbolized the original concentration
of sodium periodate added to the solution. This resulted in the unreacted sodium periodate which
was then multiplied by 100 to get a percentage.
Scanning Electron Microscopy
Once beads have been created, they are then fixed with a fixative containing 2%
paraformaldehyde and 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer overnight in the
fridge. The fixative is removed and put in aldehyde waste. The sample is dehydrated by a series
of increasing ethanol percentages. At each percentage, the sample is kept in ethanol for 3
minutes and this is done for two changes. The percentages of ethanol used were: 30%, 50%,
70%, 80%,85%,95% and 100%. At 100% ethanol the sample was kept in the solvent for 10
minutes with 3 changes done. All waste was put in an alcohol waste container and ethanol was
dumped off the sample at every change. After the final ethanol change the sample was put in the
critical point dryer for 45 minutes to 1 hour. The samples were then mounted with the use of
carbon tabs and coated with platinum at a thickness of 30nm. The SEM used to image 0mg and
20mg was the machine in CAVS. The JEOL 6500 was used to image the rest of the images.
Results
The alginate solution dropping into the cross-linking solution creating microbeads can be
seen in Figure 8. To compare between microbeads 20mg and the control of 0mg at a gross scale
photographic images were taken, Figure 9. At a macroscopic scale 0mg is more rounded in
appearance and does not have that distinct tail that 20mg has. Both beads resemble more of an
oval shape rather than a circle but the 20mg beads have a narrowing near one end leading to the
tail appearance. Through ImageJ the measurements of each microbead were calculated. The
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average length of each microbead was 0.38cm for 0mg and 0.2cm for 20mg microbeads. The
20mg also do not look as structurally sound as the 0mg, in some parts the membrane of the bead
looks wavered or almost torn. The images were taken via SEM imaging to better see the surface
morphology of the beads. The magnification is varied on some of images due being taken on
different SEM machines. It was attempted to get the best approximation on each machine as not
to skew results. As seen in Figure 10, the beginning at 0% oxidation the bead is round in
appearance and progressively gets more oval in shape. The oxidized beads also have more
ripples and crevices on their surface compared to the smooth surface of 0%. These imperfections
are due to sodium periodate taking hold on the molecular structure of alginate allowing it to be
more suspectable to degradation, cracks in the armor so to speak.

Figure 8

Alginate microbead formation

Alginate solution dropping via syringe into cross-linking solution in the beaker. Once dropped
beads are formed and spun as seen in the beaker.
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Figure 9

Gross Images of Alginate Microbeads at 0mg and 20mg

Images taken next to objects such as ruler and penny for scale.
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Figure 10

SEM Images of Alginate

SEM images taken at varying magnification showing differences between oxidation percentages
of alginate microbeads, 30mg microbeads were not able to be imaged due to extremely fragile
nature and fast degradation rate
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From Figure 11 the standard curve discussed in calculating degree of oxidation is seen.
Ten dilutions were taken, starting from a stock solution of 1M of sodium periodate, and most
values were of that of low concentration and absorbance. As seen in Figure 12 from the
calculations done on multiple amounts of sodium periodate, as expected, as the mass increased as
did the oxidation percentage. In addition to this, multiple tests were conducted to rule out
inconsistencies. The oxidation measurement tests were very consistent and repeatedly resulted in
the same values. As previously mentioned, the most promising beads to further study based on
these results were that of 5mg, 10mg, 20mg and 30mg due to their being under 10% oxidation.
Based on literature and experience, as the oxidation increased the alginate solution was unable to
form beads or quickly fell apart. The exact oxidation measurements are seen in Table 1.

Figure 11

Standard Curve of Sodium Periodate

Graph from which an equation was obtained that aided in calculating the oxidation percentages
of all samples tested. The standard curve is only reliable up to 100 micromoles.
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Figure 12

Oxidation Percentage of Alginate

Chart depicting oxidation percentages of alginate at varying amounts of sodium periodate
Table 1

Oxidation Percentage Correlation to Mass of Sodium Periodate

Mass of sodium periodate (mg)

Oxidation Percentage (%)

5
10
15
20
30
40
80
100
Oxidation percentage given in 3 significant figures

1.50
3.10
4.60
6.20
9.30
12.4
25.0
31.0

In conclusion, the oxidation percentages of each solution of oxidized alginate were
determined via the standard curve and equations. From that the morphology of viable microbeads
was examined from both a macroscopic and microscopic view. This can help in determining the
degradation rate and understanding the differences between the various microbeads being tested.

31

CHAPTER III
AIM II: EXAMINE DEGRADATION OF ALGINATE MICROBEADS AND EFFICIENCY
OF CELL ENCAPSULATION
Introduction
The degradation of the alginate fibrin microbead is important in this study to determine
because at each oxidation the hydrogel will degrade at a different rate. This rate is important for
the application of being a drug delivery device as it must last long enough in the body to allow a
potential targeting mechanism to find the calcium hydroxyapatite. It is also critical that the
microbead not degrade too slowly or the cell would not survive. The goal is that the microbead
would slowly degrade releasing osteoclasts to the designated site. This is optimal as this delivery
device would not have to be removed from the body and, is biocompatible and non-toxic to the
body so would cause no harm to the patient.
Before jumping to osteoclasts being encapsulated in the alginate microbeads, it must first
be determined whether cells could survive in hydrogel’s environment for an experimental period.
This was done by completing a degradation study with human VSMCs in varying oxidation
percentages. Again, this would determine if the microbeads were able to successfully encapsulate
cells, the rate of degradation with cells and cell media and cell viability in the alginate
microbeads. In a study by Zhou and Xu in which human umbilical cord mesenchymal stem cells
were encapsulated in oxidized alginate fibrin microbeads, the percentage of live cells remained
around 100% over 21 days of the experiment [40]. As this has not been done by our lab
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previously, this must be confirmed with the method and materials being used in this study. In
addition to this, the VSMCs were stained via DAPI on day seven of the cell degradation study to
view the number of cells in the beads or if had been released, in the media. Along with this, the
VSMCs were also stained to complete a live/dead assay in an additional experiment.
Aim II Specific Objectives
The main objective of this study was to determine which oxidation percentage would best
fit being a cell delivery device. Degradation studies are key to assess each alginate microbeads
degradation rate potential. It was also critical to evaluate the effectiveness of encapsulating cells
in oxidized alginate fibrin beads at various oxidation percentages. This needed to be done to
determine if there were any differences in degradation rate using cell media. Finally, the viability
of the cells encapsulated in the microbeads would be examined while in the bead and once
released.
Experimental Section
Materials/Methods
Determination of Degradation Potential
Newly formed beads were washed twice with DI water then placed in a 60 x 15mm petri
dish. Once in the petri dish each oxidation sample had 8mL of 1X PBS put in the dish. The dish
was capped and put in an incubator with the environment set at 37C and 5% CO2. The
temperature and media were used to simulate in-vivo. The beads were checked on every day for
10 days, with photographic images being taken each time.
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Cell Culture and Determination of Degradation Potential
Human Aortic VSMCs were cultured until passage 6. There were approximately 8.4
million cells in the T-75 flask. The cells were then separated into five equal parts to equal the
sets of alginate microbeads being tested. Once centrifuged at, DMEM +10% FBS (fetal bovine
serum) and 1% Pen (Penicillin) media was put in a centrifuge tube. The media was removed and
replaced with 5mL of alginate solution. This solution with the cell pellet was vortexed. This
mixture then followed the previous steps in creation of microbeads. The alginate-VSMCs
solution was dropped in a crosslinking solution containing 125mmol CaCl2 and thrombin. Each
bead should contain around 8,400 cells/bead according to the amount of alginate solution used,
original cell density and beads dropped per second. The microbeads were then collected and
washed twice with sterile water. Once placed in a petri dish, 8mL of DMEM +10% FBS +1%
Pen was put in the petri dish and each dish was put in an incubator set at 37 degrees Celsius and
5% CO2. Every 3 days 4mL of cell media was removed and replaced with fresh media in the
microbead dishes that had degraded.
DAPI staining
As 20mg and 30mg oxidized alginate microbeads had degraded, DMEM+10% FBS and
1% Pen was removed and rinsed twice with 1X PBS. VECTASHIELD Antifade Mounting
Medium with DAPI (4′,6-diamidino-2-phenylindole) stock solution at a concentration of
1.5µg/mL was added to culture media in a dark room. 50µL to the petri dishes containing 0mg,
5mg, 10mg, and 20mg and 30µL was added to the petri dishes containing 20mg and 30mg. The
cells were left to incubate for 15 minutes and imaged using the DAPI setting on Life
Technologies EVOS XL Inverted Imaging Digital Microscope.
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Live/Dead Assay
The microbeads were placed in petri dish with 5mL of DMEM +10% FBS +1% Pen
solution immediately after creation. The live/dead viability kit was purchased from Invitrogen.
To prepare the live/dead solution, 10mL of 1X sterile PBs was transferred to a 15mL centrifuge
tube. The Live Green (calcein AM) and Dead Red (EthD-1) components were warmed up in the
hands. 20µL Dead Red was added to the centrifuge tube under the BSC hood with the light
turned off. This solution was then vortexed before 5µL of Live Green was added. Again, this
solution was vortexed to ensure all components were mixed equally throughout the PBS. 125µL
of the PBS solution was added to each petri dish. The petri dishes were left to incubate under the
BSC hood for 30 minutes before being imaged. The cells were then imaged via Texas Red
setting for Dead Red and GFP for Live Green via Life Technologies EVOS XL Inverted Imaging
Digital Microscope.
Results
The degradation of the oxidized microbeads underwent several trials, the first of which as
seen in Figures 13-14, displays very little degradation over 10 days. All beads were kept at the
same conditions and taken images of at the same time each day. For the first trial, Figures 13-14,
5mg, 10mg, and 20mg were tested. It is expected that there will be no degradation from the 0mg
beads, with those acting as a control. With 30mg having an oxidation measurement of 9.3% it is
expected to start showing signs of degradation first followed by 20mg. 10mg and 0mg will not
degrade under a short time span due to low oxidation percent.
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Figure 13

Degradation Trial 1 of Alginate Microbeads through day 5

The first degradation trial of oxidized microbeads of 5mg, 10mg, 20mg versus the control of
0mg. The trial lasted for 10 days then ended after there was no sign of degradation from the
beads.
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Figure 14

Degradation Trial 1 of Alginate Microbeads through day 10

First trial of degradation from days 5 to 10. Petri dishes contained PBS

The second degradation study as seen in Figures 15-16, highlights microbeads at
periodate concentrations: 0mg, 5mg, 10mg, 20mg and 30mg. 30mg microbeads rapidly degraded
starting immediately from being put in the incubator. This is further exemplified by Figure 17,
where the degradation of 30mg is shown in increments of four hours until the twelve-hour mark.
There was slight change observed in the other concentrations of periodate throughout the ten-day
trial. At the nine day mark it was noticed in 20mg beads that some beads were beginning to
break apart.
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Figure 15

Degradation Trial 2 of Alginate Microbeads through day 5

Trial consisted of 0mg, 5mg, 10mg, 20mg and 30mg microbeads.
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Figure 16

Degradation Trial 2 of Alginate Microbeads through day 10

After 5 days 3mL of PBS were added to all petri dishes except 0mg as the PBS had lessened over
time.

39

Figure 17

Degradation of 30mg of periodate alginate microbeads

Degradation of 30mg microbeads within a 12-hour period. Images taken every 4 hours starting at
creation of beads.
Starting from day 1 of the degradation study completing with VSMCs encapsulated in the
microbeads 30mg microbeads were already degrading as seen in Figure 18. The microbead is
broken near the bottom and cells can be seen to be outside of the bead in the media. At day 2,
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20mg microbeads began to show signs of degradation with complete degradation at day 3. This
was surprising as this differed from the results in the previous degradation studies performed. At
day 5 VSMCs could be seen in the media of both 20mg and 30mg. 0mg, 5mg and 10mg
microbeads did not show any signs of degradation throughout the study and the cells remained in
the beads with the membrane of the beads remaining intact.
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Figure 18

Degradation Study with VSMCs

Degradation study lasting 7 days with the last day the cells were stained with DAPI as seen in
Figure 16. Cells kept in incubator at 37C for 7 days and fed with DMEM, media replaced every 3
days in dishes where microbeads had degraded.
On the final day of the degradation trial with VSMCs in the alginate microbeads, DAPI
was added to the media to stain the cells present in the petri dish. The results of the DAPI stain
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can be seen in Figures 19-23. In Figures 19-23 the cells were still encapsulated in the
microbeads at day 7 of the degradation study and thus appeared as circular in appearance
compared to their normal shape of spread out. All these samples had the same number of cells
present in the beads, and the differences between each were negligible. This can be seen in
Figures 22-23 where the cells had been released from the microbeads, as the beads had
degraded. The cells are spread out and “leggy” as is typical of VSMCs. In comparing 20mg
microbeads to 30mg microbeads, the former had more VSMCs present. The 30mg DAPI images
are also a bit fuzzy which led to decreased visibility in that sample. When comparing 20mg
microbeads to 0mg microbeads it is difficult to determine which had the most cells present as
most of the cells still present in the beads were varied in their z-position. At best 20mg
microbeads had the same amount or less than the 0mg sample.
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Figure 19

0mg alginate microbeads DAPI staining

Left side is a microscopic image with the right being the same image being viewed via
fluorescence. Three images were taken all around the sample. Image taken on day 7 of
degradation trial
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Figure 20

5mg oxidized alginate fibrin microbeads DAPI stain

Left side is a microscopic image with the right being the same image being viewed via
fluorescence. Three images were taken all around the sample. Images taken on day 7 of
degradation trial.
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Figure 21

10mg oxidized alginate fibrin microbeads DAPI stain

Left side is a microscopic image with the right being the same image being viewed via
fluorescence. Three images were taken all around the sample. Images taken on day 7 of
degradation trial.
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Figure 22

20mg oxidized alginate fibrin microbeads DAPI stain

Left side is a microscopic image with the right being the same image being viewed via
fluorescence. Three images were taken all around the sample. Images taken on day 7 of
degradation trial.
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Figure 23

30mg oxidized alginate fibrin microbeads DAPI stain

Left side is a microscopic image with the right being the same image viewed via fluorescence.
Three images were taken all around the sample. Images taken on day 7 of degradation trial.
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Figure 24

Live/Dead Assay of 0mg microbeads

Cells were stained via the protocol outlined for Live/Dead, images taken on days 0 and 3.
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Figure 25

Live/Dead Assay of 20mg microbeads

Cells were stained via the protocol outlined for Live/Dead, images taken on days 0 and 3.

From the Live/Dead study it was concluded that both microbeads encapsulated the
VSMCs and had an environment suitable to the viability of cells (Figures 24 and 25). When
compared with 0mg microbeads, 20mg microbeads had fewer live cells. This could be due to the
pliable nature of the bead due to oxidation and a faster degradation time.
In conclusion, the alginate microbeads were successfully created through the methods
described above with varying degrees of oxidation. As seen in Figure 11, each percent of
oxidation influenced the morphology of the microbeads. Also in the degradation studies, Figures
13-17, the higher oxidation the faster the degradation rate. In Figure 15, when 30mg beads is
compared to the other concentrations of beads, it has completely degraded by day 1.
The degradation study including cells saw 20mg microbeads degrade faster than
expected, and quickly turning into fibers as seen in Figure 18. This figure also displays VSMCs
in the later days of the study in the microbeads that had degraded, 20mg and 30mg. On the last
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day of the study, these cells were stained with DAPI and can be seen in Figures 19-23. From
these figures 20mg shows more VSMCs present when compared to 30mg. In the case of the
VSMCs still encased in the beads (0mg,5mg and 10mg) there was negligible difference. Finally
in an attempt at Live/Dead staining, the difference between 0mg and 20mg can be seen in 20mg
showcasing the typical VSMC shape and 0mg still containing the cells so the image is circular.
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CHAPTER IV
DISCUSSION
The overarching goal of this study is to discover a viable non-invasive, biocompatible
treatment to reverse the effects of cardiovascular calcification. As vascular calcification is a comorbidity to other cardiovascular diseases reversing this disease would in turn have positive
effects on other vascular afflictions as well. The end goal is to encapsulate osteoclasts in
oxidized alginate fibrin microbeads and target the deposited mineral via osteogenic VSMCs by a
targeting mechanism. To reach this goal: creation of the beads, determination of oxidation
percentage, degradation potential of each oxidation percentage and encapsulation efficiency of
the microbeads had to first be determined. This study focused on the first steps to create this cell
delivery device.
To create the oxidized alginate fibrin microbeads many trials were conducted to achieve
the desired the oxidation percentage of around 7.5% that previously has been mentioned to be
most successful in its degradation potential. Previous lab notes and literature review were both
used to create a procedure that was in more detail and gave more success in experiment
repeatability. Once multiple variations of oxidations of alginate microbeads had been created, the
oxidation degree had to be determined. This was a successful with a standard curve and literature
review. It also aided in understanding that previous testing of alginate solutions that were not
able to form due to their oxidation percentages being too high, larger than 10%. Once this was
discovered the focus was on creating microbeads that were less than 10% but as close to the
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optimal 7.5% as possible. Oxidation percentages 1.5%, 3.1%, 6.2% and 9.3% were created and
underwent further testing. As from the SEM imaging, the microbeads became more cracked on
the surface and elongated as the oxidation percentage increased. Especially so in the case of
9.3% where it was difficult for the beads to keep their shape and did not survive the process of
fixation to image. This could be due to the fact that this percentage is very close to 10% where is
known that the beads are very hard to handle and do not last long. This percentage was evaluated
as a contrast to the others not as a viable option for the future and to show that the alginate
microbeads can form and degrade. This is seen in the degradation studies where 9.3% or 30mg of
sodium periodate quickly degraded and the other percentages or concentrations did not change
within the experimental study.
To prove that oxidized alginate fibrin is a viable option for a cell delivery device, VSMCs
were successfully encapsulated in most of the oxidation percentages. Although 6.2% microbeads
degraded quicker than expected, when compared to previous degradation studies, there were
viable cells within the cell media. This is exemplified from the DAPI staining done on day 7 of
the degradation study. There were several instances of VSMCs that had been released from the
6.2% microbead and had attached to the petri dish surface. This was not so much the case for
9.3%, when the beads degraded, the VSMCs were few and this could be due to them not being
able to be encapsulated in a bead whose membrane was very thin and structure was
unsubstantial. 9.3% microbeads did show some VSMCs from the DAPI staining but these cells
were less mature and not in as abundance as the former. The live/dead staining of the control,
0%, and 6.2% microbeads was completed to show that the microbead provided a viable
environment for the cells. When compared between the amount of live and dead cells, there were
more live cells in both oxidation percentages. It was expected as mentioned previously that the
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microbeads were expected to degrade within 10 days in comparison to similar studies. This could
be due to the conditions at which the VSMCs were kept, or the amount of PBS used in the petri
dishes. Over time the amount of PBS lessened in the dishes containing oxidized microbeads, the
PBS should have been frequently changed with fresh PBS. The lower oxidation percentages did
not show signs of degradation and so the cells were kept inside the beads during the experiment.
The cells were similarly as stained with DAPI and could be seen as circular dots inside of the
cell.
Through all these experiments it is determined that the optimal oxidation percentage for
the cell delivery device being proposed out of the ones evaluated would be that of 6.2%. This is
due to the lower percentages showing no signs of degradation after 10 days and 9.3.%
microbeads had a quick degradation time and could not withstand any mechanical stress. In
addition, 6.2% microbeads could both successfully encapsulate and release viable VSMCs. The
lower oxidations did not release the VSMCs within the experimental timeframe, which could
lead to death of the cells from the increased time in the delivery device. On the other hand, 9.3%
microbeads were not able to encapsulate the cells to the same degree the 6.2% microbeads were.
This was evident in the amount of VSMCs present in the DAPI stain. An explanation for this
could be that because the 9.3% microbeads degraded so quickly, the VSMCs did not have
anything to attach to and overtaken by the debris of alginate-fibrin.
In conclusion the studies of creation of alginate fibrin microbeads, determining oxidation
percentage, degradation potential of oxidized alginate fibrin microbeads and cell encapsulation
potential of oxidized alginate fibrin microbeads were successful. The most critical of these is
determining which oxidation percentage would be most suitable for the cell delivery device
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trying to create. This conclusion draws on all the studies and is important in making another step
towards the ultimate goal of a cell therapy for vascular calcification.

55

CHAPTER V
FUTURE WORKS
This study proves that oxidized alginate fibrin microbeads can be successfully created via
the prescribed methods. These microbeads and variations of oxidations were tested to determine
their morphology, degradation rate and encapsulate efficiency. Specifically, SEM imaging,
degradation studies with PBS, degradation study with VSMCs and DMEM media and DAPI
staining were performed. From these studies it was proven that oxidized alginate fibrin
microbeads would be viable candidate for the proposed cell delivery device. However, to ensure
the best product of microbead, the study must be expanded to reduce variability in the samples,
increase and mechanical strength of the microbead, targeting mechanism for calcium and finally
and in-vitro model. The future works include the following objectives:
1.

Add 24mg of sodium periodate to achieve the desired 7.5% oxidation

2.

Incorporate a drying method introduced to the microbeads after cross-linking [43]

3.

Experiment with molecular weight of sodium alginate in relation with crosslinking effectiveness [53]

4.

Investigate human vitronectin and other calcium hydroxyapatite targeting
methods and perform experiment to determine degree of calcium uptake by
osteoclasts encapsulated in oxidized alginate fibrin microbeads with targeting
mechanism [48]

5.

Perform mechanical testing on preferred oxidation percentage vs. control and
investigate the use of a coating to aid in mechanical strength such as silk fibroin
[49]
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6.

Use an in-vitro model to conduct administration of cell therapy by injection, and
observe osteoclast effect on the hydroxyapatite deposited within the ECM by
means of a calcium quantification kit

For the proposed cell therapy to come to fruition, these steps must be taken especially
that of the in-vitro model. This is critical to prove the hypothesis that osteoclasts released from
oxidized alginate fibrin microbeads can remove the calcium hydroxyapatite found in the arteries
in a comparable manner to seen in the bone turnover process. The studies present here prove that
oxidized alginate fibrin microbeads do degrade thus have potential as a biodegradable and
biocompatible cell delivery device. Other suggestions of future works would only enhance the
microbeads potential in terms of mechanical strength, degradation rate and allowing microbead
to be drawn to the deposited mineral by means of calcium targeting. These suggestions hold
promise towards a bright future for the treatment of cardiovascular calcification.
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